WO2013011184A3 - Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes - Google Patents

Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes Download PDF

Info

Publication number
WO2013011184A3
WO2013011184A3 PCT/ES2012/070541 ES2012070541W WO2013011184A3 WO 2013011184 A3 WO2013011184 A3 WO 2013011184A3 ES 2012070541 W ES2012070541 W ES 2012070541W WO 2013011184 A3 WO2013011184 A3 WO 2013011184A3
Authority
WO
WIPO (PCT)
Prior art keywords
seq
fragment
leishmaniasis
immunotherapy
leishmania infantum
Prior art date
Application number
PCT/ES2012/070541
Other languages
English (en)
French (fr)
Other versions
WO2013011184A2 (es
Inventor
Maria del Carmen THOMAS CARAZO
Manuel Carlos LÓPEZ LÓPEZ
Darién LEDESMA ARROYO
Original Assignee
Consejo Superior De Investigaciones Científicas (Csic)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Superior De Investigaciones Científicas (Csic) filed Critical Consejo Superior De Investigaciones Científicas (Csic)
Priority to BR112014001086A priority Critical patent/BR112014001086A2/pt
Priority to US14/234,075 priority patent/US9926349B2/en
Priority to CN201280045285.XA priority patent/CN103890004B/zh
Publication of WO2013011184A2 publication Critical patent/WO2013011184A2/es
Publication of WO2013011184A3 publication Critical patent/WO2013011184A3/es
Priority to US15/895,907 priority patent/US10919946B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6043—Heat shock proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una secuencia nucleotídica aislada caracterizada por codificar para la proteína PFR1 de Leishmania infantum o un fragmento de la misma, dicha proteína PFR1 o un fragmento de la misma comprende al menos un epítope inmunodominante seleccionado entre el siguiente grupo: SEQ ID No: 1, SEQID No: 2, SEQ ID No: 3, SEQ ID No: 4, SEQ ID No: 5, SEQ ID No: 6, SEQ ID No: 7 y SEQ ID No: 8, donde dicho epítope inmunodominante es capaz de inducir una respuesta inmunológica T citotóxica específica de antígeno en un animal, frente a los kinetoplástidos que causan la enfermedad de la leishmaniosis. Dichos epítopes inmunodominantes son activadores de linfocitos T citotóxicos y presentan alta afinidad de unión por la molécula MHC de clase I de tipo A2.
PCT/ES2012/070541 2011-07-21 2012-07-17 Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes WO2013011184A2 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
BR112014001086A BR112014001086A2 (pt) 2011-07-21 2012-07-17 molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes
US14/234,075 US9926349B2 (en) 2011-07-21 2012-07-17 Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
CN201280045285.XA CN103890004B (zh) 2011-07-21 2012-07-17 由具有特定免疫显性表位的婴儿利什曼虫pfr1蛋白片段组成的嵌合分子可用于抗利什曼病的免疫疗法
US15/895,907 US10919946B2 (en) 2011-07-21 2018-02-13 Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP201131257 2011-07-21
ES201131257 2011-07-21

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US14/234,075 A-371-Of-International US9926349B2 (en) 2011-07-21 2012-07-17 Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes
US15/895,907 Division US10919946B2 (en) 2011-07-21 2018-02-13 Chimeric molecule useful in immunotherapy for leishmaniasis, which includes a fragment of the PFR1 protein of leishmania infantum with specific immunodominant epitopes

Publications (2)

Publication Number Publication Date
WO2013011184A2 WO2013011184A2 (es) 2013-01-24
WO2013011184A3 true WO2013011184A3 (es) 2013-03-14

Family

ID=47558549

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2012/070541 WO2013011184A2 (es) 2011-07-21 2012-07-17 Molécula quimerica util en inmunoterapia frente a la leishmaniosis, que comprende un fragmento de la proteina pfr1 de leishmania infantum con epitopes especificos inmunodominantes

Country Status (4)

Country Link
US (2) US9926349B2 (es)
CN (1) CN103890004B (es)
BR (1) BR112014001086A2 (es)
WO (1) WO2013011184A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0915605B8 (pt) * 2008-05-08 2021-09-08 The Government Of The Us Secretary Of The Dept Of Healt & Human Services Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
BR112014001086A2 (pt) * 2011-07-21 2017-02-21 Consejo Superior De Investig Cientificas/Csic molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes
ES2795149B2 (es) 2020-06-08 2022-07-04 Univ Madrid Complutense Quimera sintetica multiepitopica como vacuna y tratamiento frente a leishmaniosis en mamiferos

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2563796A1 (en) * 2004-04-23 2005-11-24 The University Of Georgia Research Foundation, Inc. Diagnostic assay for trypanosoma cruzi infection
CA2700000A1 (en) * 2007-07-30 2009-02-05 Rick L. Tarleton Diagnostic assay for trypanosoma cruzi infection
AR064593A1 (es) * 2007-10-31 2009-04-15 Baeremaecker Barros Carlos De Una vacuna multicomponente o monocomponente para ser utilizada contra la enfermedad de chagas, composiciones farmaceuticas que las contienen, procedimiento para la obtencion del inmunogeno de dichas vacunas y acido nucleico utilizado en dicho procedimiento.
BR112014001086A2 (pt) * 2011-07-21 2017-02-21 Consejo Superior De Investig Cientificas/Csic molécula quimérica útil na imunoterapia contra a leishmaniose, a qual compreende um fragmento da proteína pfr1 de leishmania infantum com epítopos específicos imunodominantes

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
DATABASE BASE DE DATOS GENBANK, NC 5 September 2004 (2004-09-05), WAEGER, F ET AL.: "Paraflagellar rod protein 1 [Leishmania infantum]", accession no. AU09406 *
DATABASE NCBI NATIONAL INSTITUTES OF HEALTH; 5 September 2004 (2004-09-05), WAEGER, F. ET AL.: "Paraflagellar rod protein 1 [Leishmania infantum]", accession no. AU09406 *
LEDESMA-ARROYO, D.: "Identificacion of epitopes CD8+ in the proteina PFR1 of Leishmania infantum and determinacion of su inmunogenicidad como vacuna plasmídica", TESINA OF LICENCIATURA, 17 December 2010 (2010-12-17), UNIVERSIDAD OF GRANADA, pages 1 - 27, XP055102316 *
LEDESMA-ARROYO, D: "Identificacion de epitopes CD8+ en la proteína PFR1 de Leishmania infantum y determinación de su inmunogenicidad como vacuna plasmidica", TESINA DE LICENCIATURA, 17 December 2010 (2010-12-17), pages 1 - 27, XP055102316 *
MORELL, M ET AL.: "The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection", VACCINE, vol. 24, no. 49-50, 30 November 2006 (2006-11-30), pages 7046 - 7055, XP028011435 *
MORELL, M. ET AL.: "The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection", VACCINE, vol. 24, no. 49-50, 30 November 2006 (2006-11-30), pages 7046 - 7055, XP028011435 *
PLANELLES, L ET AL.: "DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection", INFECTION AND IMMUNITY, vol. 69, no. 10, 1 October 2001 (2001-10-01), pages 6558 - 6563, XP002496367 *
PLANELLES, L. ET AL.: "DNA immunization with Trypanosoma cruzi HSP70 fused to the KMP11 protein elicits a cytotoxic and humoral immune response against the antigen and leads to protection", INFECTION AND IMMUNITY., vol. 69, no. 10, 1 October 2001 (2001-10-01), pages 6558 - 6563 *

Also Published As

Publication number Publication date
CN103890004A (zh) 2014-06-25
US20180312555A1 (en) 2018-11-01
US20140286974A1 (en) 2014-09-25
WO2013011184A2 (es) 2013-01-24
US9926349B2 (en) 2018-03-27
BR112014001086A2 (pt) 2017-02-21
US10919946B2 (en) 2021-02-16
CN103890004B (zh) 2018-02-02

Similar Documents

Publication Publication Date Title
WO2017147383A8 (en) Modified cells for immunotherapy
RU2018132044A (ru) Антитела против тау
MX348071B (es) Variantes de fc.
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
RU2014144143A (ru) Химерные антигенные рецепторы, нацеленные на антиген созревания в-клеток
WO2013059885A3 (en) Polypeptide constructs and uses thereof
CA2848209C (en) T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
IN2012DN02368A (es)
WO2012046061A3 (en) Clostridium difficile antigens
EA200801907A1 (ru) Химерный аденовирусный вектор, иммуногенная композиция на его основе, способ индукции иммуного ответа с его помощью, иммуногенная композиция агониста tlr-3 и вектора экспрессии гетерологичного белка, способ индукции иммунного ответа с помощью агониста tlr-3 и вектора экспрессии гетерологичного белка и выделенная нуклеиновая кислота
WO2012088247A3 (en) Anti-c5/c5a/c5adesr antibodies and fragments
WO2007146401A3 (en) Denatured collagen peptides and uses thereof
NZ630847A (en) Anti-sema4d antibodies and epitopes
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
WO2012018767A3 (en) Antibodies directed against il-17
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
MX2013007918A (es) Peptidos inmunogenicos monomericos y multimericos.
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
WO2011156619A3 (en) Vaccine and methods to reduce campylobacter infection
MY166152A (en) Anti-human xcr1 antibodies
GB201118394D0 (en) Vaccine
MX2015007421A (es) Proteinas de tipo espiral enrollada modificadas que tienen propiedades mejoradas.
WO2012114125A3 (en) Treatment and prevention of malaria

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2012815090

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815090

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112014001086

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 14234075

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 12815090

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112014001086

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20140116